Breast Cancer Clinical Trial
Official title:
Improving Symptom Management for Survivors of Young Adult Cancer
Verified date | February 2024 |
Source | Duke University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Symptom interference is common for survivors of young adult cancer (aged 18-39 at diagnosis) and impacts their abilities to achieve normative life goals (e.g., education, careers, independence, romantic/social relationships) as well as adhere to recommended follow-up care. Assistance with symptom management has been rated by young adult survivors as an important and unmet healthcare need; however, skill-based symptom management interventions have typically been tested among older cancer survivors and have not targeted the unique developmental needs of those diagnosed as young adults. The proposed research advances the health and wellbeing of young adult cancer survivors by creating a developmentally appropriate hybrid in-person/mHealth behavioral symptom management intervention which addresses variables (i.e., symptoms and symptom interference) consistently linked to significant social, economic, and health burden.
Status | Active, not recruiting |
Enrollment | 120 |
Est. completion date | May 30, 2024 |
Est. primary completion date | May 30, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 39 Years |
Eligibility | Young Adult Cancer Survivors Participating in Intervention Development Interviews Eligibility Criteria - Diagnosed with hematologic, breast, gastrointestinal, or endocrine cancers, melanoma, or germ cell tumors - Diagnosed with cancer as a young adult - Under the care of a medical provider at the Duke Cancer Institute - Completed curative treatment involving multimodal therapy within the last five years - Able to speak and read English - Able to give informed consent Exclusion Criteria - Nonambulatory - Major mental illness, i.e., schizophrenia - Untreated or uncontrolled mental illness, i.e., bipolar - Residence greater than 100 miles from the research site Medical Providers Participating in Intervention Development Interviews Eligibility criteria o Provide care to young adult cancer survivors at the Duke Cancer Institute Young Adult Cancer Survivor User Testers Eligibility Criteria - Diagnosed with hematologic, breast, gastrointestinal cancers, or endocrine cancers, melanoma, or germ cell tumors - Diagnosed with cancer as a young adult - Under the care of a medical provider at the Duke Cancer Institute - Completed curative treatment involving multimodal therapy within the last five years - Able to speak and read English - Able to give informed consent Exclusion Criteria - Nonambulatory - Major mental illness, i.e., schizophrenia - Untreated or uncontrolled mental illness, i.e., bipolar - Residence great than 100 miles from the research site RCT Participants Eligibility Criteria: - diagnosed with cancer as a YA (aged 18-39) - diagnosis of hematologic, breast, endocrine or gastrointestinal cancer, melanoma, or germ cell tumor - receiving care at the Duke Cancer Institute - completed curative treatment involving multimodal therapy within the last 2 years - able to speak/read English; and able to give informed consent. Exclusion Criteria: - non-ambulatory - major mental illness (i.e., schizophrenia) - untreated or uncontrolled mental illness (i.e., bipolar disorder) |
Country | Name | City | State |
---|---|---|---|
United States | Duke Cancer Institute | Durham | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Duke University | National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Sociodemographics | Age, race/ethnicity, relationship status, employment status, occupation, income, and years fo education | Baseline | |
Other | Disease Characteristics | Disagnosis and treatment information | Baseline | |
Other | Change in Activity: International Physical Activity Questionnaire | The International Physical Activity Questionnaire is a seven-item questionnaire that assesses the amount of time participants have spent doing physical activity (e.g., moderate physical activities, vigorous physical activities, walking) in the last seven | Baseline and again 3, 6, 9, and 12 months following the baseline assessment | |
Other | Change in Activity: Stanford LCAT | The Stanford LCAT is a categorical item that asseses the type of physical activities participants do. | Baseline and again 3, 6, 9, and 12 months following the baseline assessment | |
Other | Change in Spritual Well-Being: Functional Assessment of Chronic Illness Therapy (FACIT) | The FACIT assesses the spiritual wellbeing of participants with 12-item questionnaire on a scale from 0 = "not at all" to 4 = "very much." | Baseline and again 3, 6, 9, and 12 months following the baseline assessment | |
Other | Changes in Cancer Experience: Acceptance and Action Questionnaires for Cancer (AAQ) | The AAQ is a 7-item questionnaire to track psychological flexibility related to coping with cancer and cancer treatment. The scale ranges from 1 = "never true" to 7 "always true." Item is scored by adding all of the responses together. | Baseline and again 3, 6, 9, and 12 months following the baseline assessment | |
Other | Changes in Living in Alignment with Values: The Valuing Questionnaire (VQ) | The VQ is a 10-item self-report questionnaire with a scale 0 = "not true at all" to 6 "completely true." | Baseline and again 3, 6, 9, and 12 months following the baseline assessment | |
Primary | Intervention Satistfaction: SSTS-R | Intervention satisfaction will be assessed using the SSTS-R, a 13-item measure with the first 12-items on a five-point scale ranging from 1 "strongly disagree" to 5 "strongly disagree." The 13th item asks, "How much did the intervention help with your sypmtoms?" with 5 answer choices ranging from "made things a lot better" to made things a lot worse." | Following completion of the intervention, up to 12 months | |
Primary | Open-Ended Questions About the Program | Intervention will be evaluated using 3 open-ended questions, including the following: "1) What was the most helpful part of the program?," "2) What was the least helpful part of the program?", and "3) What suggestions do you have for us to help improve the program?" | Following completion of the intervention, up to 12 months | |
Primary | Session attendance | Treatment feasibility will be assessed by measuring the session attendance rate for each participant. | Following completion of the intervention, up to 12 months | |
Primary | Treatment Acceptability Questionnaire | The Treatment Acceptability Questionnaire is a six-item scale assessing participants' views of an intervention as acceptable, ethical, and effective.
Items are rated on a 7-point Likert scale (e.g., 1 "very unacceptable" to 7 "very acceptable). |
Following completion of the intervention, up to 12 months | |
Primary | Change in Depressive Symptoms: PROMIS Depression Short Form | Depressive Symptoms will be assessed using the PROMIS Depression Short Form, an 8-item measure assessing symptoms of depression in the last week. Participants are asked to respond to items (e.g., "I felt sad," "I felt helpless") using a five-point scale ranging from 1 "never" to 5 "always." | Baseline and again 3, 6, 9, and 12 months following the baseline assessment | |
Primary | Change in Anxiety: PROMIS Anxiety Short Form | Symptoms of Anxiety will be assessed using the PROMIS Anxiety Short Form, an 8-item measure assessing symptoms of anxiety in the last week. Participants are asked to respond to items (e.g., "I felt nervous," "I felt tense") using a five-point scale ranging from 1 "never" to 5 "always". | Baseline and again 3, 6, 9, and 12 months following the baseline assessment | |
Primary | Change in Symptom Interference: Illness intrusiveness rating scale | Symptom interference will be assessed using the Illness Intrusiveness Rating Scale (IIRS). The IIRS assesses the extent to which an illness and/ or its treatments interfere with 13 quality of life domains (e.g., health, diet, work, sex life, active recreation). Items are rated on a 7-point scale from 1 "not very much" to 7 "very much." | Baseline and again 3, 6, 9, and 12 months following the baseline assessment | |
Primary | Use of Intervention Strategies | Participants' use of intervention strategies will be assessed using a measure developed specific to components of the proposed intervention. Participants will be asked about how frequently treatment strategies discussed in session have been used outside of session since the previous session or last assessment depending on the timing of the questionnaire. A scale ranging from 0 "not at all" to 5 "2 or more times a day" will be used. | Following completion of the intervention, up to 12 months | |
Primary | Self-reported use of the Mobile Application | Participants' use of the mobile application will be assessed using a measure developed specific to components of the proposed mobile application.
Participants will be asked about how frequently they have used components of the mobile application outside of session since the previous session or last assessment depending on the timing of the questionnaire. A scale ranging from 0 "not at all" to 5 "2 or more times a day" will be used. |
Following completion of the intervention, up to 12 months | |
Primary | Change in Pain: Brief Pain Inventory | The Brief Pain Inventory is a 9-item, self-report measure assessing pain severity and interference from pain across important life domains (e.g., general activity, work, relations with others). Participants rate their pain on a scale from 0 "no pain" to 10 "pain as bad as you can imagine." | Baseline and again 3, 6, 9, and 12 months following the baseline assessment | |
Primary | Change in Fatigue: PROMIS Fatigue Short Form | Fatigue will be assessed using the PROMIS Fatigue Scale, a 6-item self-report measure of fatigue. Participants are asked to think about the last week when responding to each item (e.g., "In the past 7 days, how run-down did you feel, on average?"). Respon | Baseline and again 3, 6, 9, and 12 months following the baseline assessment | |
Secondary | Group Therapy Experiences Scale | The 17-item Group Therapy Experiences Scale will be used to assess the level of cohesion among group members (e.g., development of positive relationships, comfort level with other group members). Items 1-16 are rated on a 5-point scale with 1 = "strongly agree" to 5 = "strongly disagree." Item 17 is an open-ended question, "was there something in the group today that helped or hindered you?"relationships, comfort level with other group members). Items are rated on a 4-point scale with 1= "strongly disagree" to 4= "strongly agree." | Following completion of the intervention, up to 12 months | |
Secondary | Change in Social Isolation: PROMIS Social Isolation Scale | The PROMIS Social Isolation Scale is a 6-item measure is used to assess social isolation. Participants are asked to rate each item (e.g., "I felt left out," "I feel that people avoid talking to me") on a scale from 1= "never" to 5= "always." | Baseline and again 3, 6, 9, and 12 months following the baseline assessment | |
Secondary | Change in Self-Efficacy: The Self-Efficacy for Managing Chronic Disease Scale | The Self-Efficacy for Managing Chronic Disease Scale is a 6-item scale. Participants rate their confidence in keeping pain, fatigue, emotional distress, and other symptoms from interfering with things they want to do on a scale from 1 "not at all confident" to 10 "totally confident." | Baseline and again 3, 6, 9, and 12 months following the baseline assessment | |
Secondary | Change in Self-Efficacy: PROMIS Self-Efficacy for Managing Chronic Conditions - Managing Symptoms - Short Form 4a | The PROMIS Self-Efficacy for Managing Chronic Conditions - Managing Symptoms - Short Form 4a is a 4-item scale. Participants rate their confidence in managing their symptoms during daily activities, with relationships with friends and family, in a public place, and working with their doctor to manage these symptoms on a scale from 1 = "I am not at all confident" to 5 "I am very confident." | Baseline and again 3, 6, 9, and 12 months following the baseline assessment | |
Secondary | Change in Emotional Support: PROMIS Emotional Support-Short Form | The PROMIS Emotional Support Short Form is a 6-item measure used to assess emotional support. Participants are asked to rate each item ("I have someone who will listen to me when I need to talk," "I have someone to talk with when I have a bad day") on a scale from 1= "never" to 5= "always." | Baseline and again 3, 6, 9, and 12 months following the baseline assessment | |
Secondary | Change in Instrumental Support: PROMIS Instrumental Support-Short Form | The PROMIS Instrumental Support Short Form is a 6-item measure used to assess instrumental support. Participants are asked to rate each item (e.g., "Do you have someone to take you to the doctor if you needed it?," "Do you have someone to prepare your meals if you are unable to do it yourself?") on a scale from 1= "never" to 5= "always." | Baseline and again 3, 6, 9, and 12 months following the baseline assessment | |
Secondary | Change in Informational Support: PROMIS Informational Support-Short Form | The PROMIS Informational Support Short Form is a 6-item measure used to assess informational support. Participants are asked to rate each item (e.g., "I have someone to turn to for suggestions about how to deal with a problem," "I have someone to give me information if I need it") on a scale from 1= "never" to 5= "always." | Baseline and again 3, 6, 9, and 12 months following the baseline assessment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |